Canada will be the first commercial market to launch i-FACTOR+ Matrix. The technology is currently being studied in an FDA IDE trial targeting lumbar fusion.
The artificial intelligence technology leads to precise surgery and optimal knee implant positioning, resulting in improved quality of life for patients.
Financing will provide 7D with the capital to grow existing operations, further develop new products and continue its expansion into international markets.
The designation and funding from the U.S. DoD will accelerate R&D for the mechanically functional total meniscus replacement that is resorbed by the body.
The Kiva Vertebral Compression Fracture Treatment is a unipedicular PEEK implant-based solution that has seen clinical and commercial success in the U.S.